Stifel has initiated coverage of Cytokinetics (NASDAQ:CYTK) with a buy rating, citing its drug aficamten. The bank noted the stock was "out of favor" in the wake of a "controversial" deal with Royalty ...

Stifel analysts initiated coverage on Cytokinetics shares (NASDAQ:CYTK), assigning a Buy rating and setting a price target of ...

Cytokinetics, Inc. (CYTK), a biopharmaceutical company focused on muscle biology, on Monday announced the launch of the AMBER-HFpEF ...

Canaccord Genuity analyst Caitlin Burrows initiated coverage on Orthofix Medical Inc. OFIX with a Buy rating and announced a ...

Stifel initiated coverage of Cytokinetics (CYTK) with a Buy rating and $80 price target Cytokinetics “is an out-of-favor stock” following the ...

The CEO of Cytokinetics says the company is not for sale. That doesn't mean it would turn away potential suitors.

Cytokinetics' hopes of resurrecting cardiac myosin activator omecamtiv mecarbil have suffered another setback, after the drug failed to show a benefit in a phase 3 heart failure study. In the ...

Cytokinetics could make more geography-centric deals as regulators in the United States, Europe and China review the company's potential blockbuster drug for approval. Cytokinetics Inc. has a new ...

Cytokinetics, Incorporated announced the granting of stock options and restricted stock units (RSUs) to nine new employees on December 31, 2024, as part of their employment inducement. The company ...

Technical analysis for Cytokinetics Incorporated CYTK including support levels resistance levels and stop losses for CYTK ...

PDUFA Target Action Date for Aficamten Set for September 26, 2025;Commercial Launch Preparations Underway for First Potential Approval Five-Year Aspirations Outline Corporate Strategies to ...

SOUTH SAN FRANCISCO, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq: CYTK) today provided guidance for corporate milestones expected to occur in 2025 and outlined its ...